April 2021, Drugs Monitor, Page 6

(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients

April 7, 2021

Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages https://www.medrxiv.org/content/10.1101/2021.03.04.21252167v1 The study was conducted from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment,… Continue reading "(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients"

(08 Mar 2021) Bromhexine Hydrochloride-prophylactic treatment was not associated with a lower positive swab PCR test

April 7, 2021

Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study https://www.medrxiv.org/content/10.1101/2021.03.03.21252855v1 NCT04405999- In a single-center randomized open-label study medical staff managing patients with suspected and confirmed COVID-19 were enrolled and followed-up for 8 weeks. 50 participants without a… Continue reading "(08 Mar 2021) Bromhexine Hydrochloride-prophylactic treatment was not associated with a lower positive swab PCR test"

(04 Mar 2021) Nitazoxanide- significant viral load reduction ≥ 35% from baseline up to day 7 of treatment

April 7, 2021

Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study https://www.medrxiv.org/content/10.1101/2021.03.03.21252509v1 NCT04463264- The objective of this study was to evaluate the efficacy and safety of Nitazoxanide in reducing the SARS-COV 2 viral… Continue reading "(04 Mar 2021) Nitazoxanide- significant viral load reduction ≥ 35% from baseline up to day 7 of treatment"

Month: April 2021

(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients

(08 Mar 2021) Bromhexine Hydrochloride-prophylactic treatment was not associated with a lower positive swab PCR test

(04 Mar 2021) Nitazoxanide- significant viral load reduction ≥ 35% from baseline up to day 7 of treatment